HolmesC.J., FaictD.Peritoneal dialysis solution biocompatibility: Definitions and evaluation strategies.Kidney Int Suppl2003; 88: S50–6.
2.
Di PaoloN., GarosiG., PetriniG., TraversariL., RossiP.Peritoneal dialysis solution biocompatibility testing in animals.Perit Dial Int1995; 15(Suppl 3): S61–9.
3.
DaviesS.J., BryanJ., PhillipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
4.
WilliamsJ.D., CraigK.J., TopleyN., von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane in patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
5.
WilliamsJ.D., CraigK.J., von RuhlandC., TopleyN., WilliamsG.The natural course of peritoneal membrane biology during peritoneal dialysis.Kidney Int Suppl2003; 88: S43–9.
6.
De VrieseA.S., MortierS., LameireN.H.Neoangiogenesis in the peritoneal membrane: Does it play a role in ultrafiltration failure?Nephrol Dial Transplant2001; 16: 2143–5.
7.
De FijterC.W.H., VerbrughH.A., PetersE.D.J., OeP.L., van der MeulenJ., VerhoefJ.In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol1993; 39: 75–80.
8.
MactierR.A., SprosenT.S., GokalR., WilliamsP.F., LindberghM., NaikR.B.Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.Kidney Int1998; 53: 1061–7.
9.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12: 1046–51.
WitowskiJ., KorybalskaK., WisniewskaJ., BreborowiczA., GahlG.M., FreiU.Effect of glucose degradation products on human peritoneal mesothelial cell function.J Am Soc Nephrol2000; 11: 729–39.
12.
WitowskiJ., WisniewskaJ., KorybalskaK., BenderT.O., BreborowiczA., GahlG.M.Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.J Am Soc Nephrol2001; 12: 2434–41.
13.
WieslanderA., LindenT.Glucose degradation products and cytotoxicity in PD fluids.Perit Dial Int1996; 16(Suppl 1): S114–18.
14.
LindenT., CohenA., DeppischR., KjellstrandP., WieslanderA.3,4-Dideoxyglucosone-3-ene (3,4-DGE): A cytotoxic glucose degradation product in fluids for peritoneal dialysis.Kidney Int2002; 62: 697–703.
15.
NakayamaM., KawaguchiY., YamadaK., HasegawaT., TakazoeH., KatohN.Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.Kidney Int1997; 51: 182–6.
16.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration.Nephrol Dial Transplant1999; 14: 1541–9.
17.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC., on behalf of the Euro Balance Trial Group. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
18.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
19.
JonesS., HolmesC.J., KredietR.T., MackenzieR., FaictD., TranæusA., on behalf of the Bicarbonate/Lactate Study Group. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.Kidney Int2001; 59: 1529–38.
20.
Tranæus A, for the Bicarbonate/Lactate Study Group.A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution — clinical benefits.Perit Dial Int2000; 20: 516–23.
21.
SimonsenO., WieslanderA., LandgrenC., RippeB.Less infusion pain and elevated level of cancer antigen 125 by the use of a new more biocompatible PD fluid.Adv Perit Dial1996; 12: 156–60.
22.
LeeH.Y., ParkH.C., SeoB.J., DoJ.Y., YunS.R., SongH.Y.Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).Perit Dial Int2005; 25: 248–55.
23.
ZeierM., SchwengerV., DeppischR., HaugU., WeigelK., BahnerU.Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?Kidney Int2003; 63: 298–305.
24.
PaniaguaR., AmatoD., VoneshE., Correa-RotterR., RamosA., MoranJ.Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized controlled trial.J Am Soc Nephrol2002; 13: 1307–20.
